InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	33.26M 29M 26.82M 25.13M 47.06M 3.14B 47.43M 318M 123M 1.54B 125M 122M 5.36B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	33.26M 29M 26.82M 25.13M 47.06M 3.14B 47.43M 318M 123M 1.54B 125M 122M 5.36B	EV / Sales 2026 *	3.21x	EV / Sales 2027 *	1.52x
Free-Float	80.17%	Yield 2026 *	-	Yield 2027 *	-

06-08	Inspiremd Enrolls First Patient in Cguardians Iii Pivotal Study of Switchguard Neuro Protection System for Use in Tcar Procedures	CI
05-22	InspireMD, Inc. Announces Not Seek Re-Election of Paul Stuka as Director	CI
05-14	InspireMD, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 04:20 PM
05-05	InspireMD, Inc., Q1 2026 Earnings Call, May 04, 2026
05-04	InspireMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-02	FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System -- Update	DJ
05-01	InspireMD Says FDA Approved Application to Begin SwitchGuard Neuro Protection System CGUARDIANS III Study	MT
05-01	InspireMD Withdraws Guidance, Recalls CGuard Prime	DJ
05-01	InspireMD, Inc. Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System	CI
05-01	Inspiremd Inc Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the Switchguard Neuro Protection System	CI
03-18	InspireMD, Inc., Q4 2025 Earnings Call, Mar 18, 2026
03-18	InspireMD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-18	InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026	CI

12/06/23	Piper Sandler Initiates InspireMD at Overweight With $3 Price Target	MT
17/05/23	Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating	MT

06-15	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
06-12	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
06-11	InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures	AQ
06-08	InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures	AQ
05-06	InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference	AQ

Manager	Title	Age	Since
Marvin Slosman CEO	Chief Executive Officer	62	01/01/2020
Michael Lawless DFI	Director of Finance/CFO	58	25/06/2025
Shany Barel CTO	Chief Tech/Sci/R&D Officer	-	-

InspireMD Stock NYSE

Stocks

Medical Equipment, Supplies & Distribution

Valuation: InspireMD

Latest news : InspireMD

Last Transcript: InspireMD

Analysts' recommendations: InspireMD

Press Releases: InspireMD

Quotes and Performance

Managers and Directors: InspireMD

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Paul Stuka CHM	Chairman	71	02/06/2017
Michael Berman BRD	Director/Board Member	68	07/02/2013
Marvin Slosman BRD	Director/Board Member	62	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INSPIREMD	-3.81%	+32.01%	-	-	33.26M
STRYKER CORPORATION	+2.21%	-1.41%	-17.54%	+4.57%	118B
SMITH & NEPHEW PLC	-0.66%	-0.71%	+4.75%	-9.49%	12.63B
GLAUKOS CORPORATION	+2.57%	+3.05%	+27.69%	+92.97%	7.67B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.48%	-3.09%	-46.17%	-71.45%	4.07B
DOUBLE MEDICAL TECHNOLOGY INC.	+1.51%	+0.28%	+19.85%	+35.05%	2.55B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.94%	-1.24%	-13.34%	-15.72%	1.77B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.21%	-4.06%	+3.70%	-20.10%	1.59B
L&C BIO CO.,LTD	+5.36%	+9.88%	+200.71%	+151.86%	1.49B
Average	+0.93%	+0.99%	+22.46%	+20.96%	18.72B
Weighted average by Cap.	+1.92%	+0.74%	-11.04%	+7.33%

	2026 *	2027 *
Net sales	10.38M 9.05M 8.37M 7.84M 14.68M 978M 14.8M 99.33M 38.49M 482M 38.94M 38.1M 1.67B	21.92M 19.11M 17.67M 16.56M 31.01M 2.07B 31.26M 210M 81.3M 1.02B 82.25M 80.49M 3.53B
Net income	-	-
Net Debt	-	-